Aegerion Pharmaceuticals said the FDA approved its drug for a rare cholesterol disease, but will require safety precautions because of its potential liver toxicity.
WSJ.com: What's News US, Wall Street Journal
Mon, 12/24/2012 - 11:38am
Aegerion Pharmaceuticals said the FDA approved its drug for a rare cholesterol disease, but will require safety precautions because of its potential liver toxicity.